Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis

Redox Biology

Volumn 11, Issue , 2017, Pages 254-262

  Roh, Jong Lyel ^a   Kim, Eun Hye ^a   Jang, Hyejin ^a   Shin, Daiha ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Artensunate; Ferroptosis; Head and neck cancer; Nrf2; Reactive oxygen species; Resistance

Indexed keywords

ARTESUNATE; CHONDROITIN SULFATE IRON; CISPLATIN; GLUTATHIONE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TRIGONELLINE; TROLOX C; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID; ALKALOID; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; CHROMAN DERIVATIVE; CYCLOHEXYLAMINE DERIVATIVE; FERROSTATIN-1; HMOX1 PROTEIN, MOUSE; IRON; KEAP1 PROTEIN, MOUSE; MEMBRANE PROTEIN; NFE2L2 PROTEIN, MOUSE; PHENYLENEDIAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; FERROPTOSIS; GENE SILENCING; GLUTATHIONE METABOLISM; HEAD AND NECK CANCER; HEAD AND NECK CANCER CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG REPOSITIONING; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ALKALOIDS; ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CHROMANS; CISPLATIN; CYCLOHEXYLAMINES; DRUG REPOSITIONING; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HEME OXYGENASE-1; HUMANS; IRON; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-E2-RELATED FACTOR 2; PHENYLENEDIAMINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85007349764     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.12.010     Document Type: Article

References (47)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012, CA. Cancer J. Clin. 65 (2015), 87–108.
2. [2] Haddad, R.I., Shin, D.M., Recent advances in head and neck cancer. N. Engl. J. Med 359 (2008), 1143–1154.
3. [3] Kong, M., Hong, S.E., Tumor regression patterns based on follow-up duration in patients with head and neck squamous cell carcinoma treated with radiotherapy or chemoradiotherapy. Clin. Exp. Otorhinolaryngol. 8 (2015), 416–421.
4. [4] Moon, S.H., Choi, J.Y., Lee, H.J., Son, Y.I., Baek, C.H., Ahn, Y.C., Ahn, M.J., Park, K., Kim, B.T., Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clin. Exp. Otorhinolaryngol. 8 (2015), 142–148.
5. [5] Petrelli, F., Coinu, A., Riboldi, V., Borgonovo, K., Ghilardi, M., Cabiddu, M., Lonati, V., Sarti, E., Barni, S., Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral. Oncol. 50 (2014), 1041–1048.
6. [6] Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., Kroemer, G., Molecular mechanisms of cisplatin resistance. Oncogene 31 (2012), 1869–1883.
7. [7] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
8. [8] Conrad, M., Angeli, J.P., Vandenabeele, P., Stockwell, B.R., Regulated necrosis: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 15 (2016), 348–366.
9. [9] Dondorp, A., Nosten, F., Stepniewska, K., Day, N., White, N., Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366 (2005), 717–725.
10. [10] Vandewynckel, Y.P., Laukens, D., Geerts, A., Vanhove, C., Descamps, B., Colle, I., Devisscher, L., Bogaerts, E., Paridaens, A., Verhelst, X., Van Steenkiste, C., Libbrecht, L., Lambrecht, B.N., Janssens, S., Van Vlierberghe, H., Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur. J. Gastroenterol. Hepatol. 26 (2014), 861–870.
11. [11] Jeong da, E., Song, H.J., Lim, S., Lee, S.J., Lim, J.E., Nam, D.H., Joo, K.M., Jeong, B.C., Jeon, S.S., Choi, H.Y., Lee, H.W., Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 6 (2015), 33046–33064.
12. [12] Kast, R.E., Boockvar, J.A., Bruning, A., Cappello, F., Chang, W.W., Cvek, B., Dou, Q.P., Duenas-Gonzalez, A., Efferth, T., Focosi, D., Ghaffari, S.H., Karpel-Massler, G., Ketola, K., Khoshnevisan, A., Keizman, D., Magne, N., Marosi, C., McDonald, K., Munoz, M., Paranjpe, A., Pourgholami, M.H., Sardi, I., Sella, A., Srivenugopal, K.S., Tuccori, M., Wang, W., Wirtz, C.R., Halatsch, M.E., A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma care. Oncotarget 4 (2013), 502–530.
13. [13] Augustin, Y., Krishna, S., Kumar, D., Pantziarka, P., The wisdom of crowds and the repurposing of artesunate as an anticancer drug. Ecancermedicalscience, 9, 2015, 50.
14. [14] Efferth, T., Benakis, A., Romero, M.R., Tomicic, M., Rauh, R., Steinbach, D., Hafer, R., Stamminger, T., Oesch, F., Kaina, B., Marschall, M., Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 37 (2004), 998–1009.
15. [15] Zhang, H., Ji, Y., Chen, Q., Jiao, X., Hou, L., Zhu, X., Zhang, Z., Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles. J. Drug Target 23 (2015), 552–567.
16. [16] Efferth, T., Giaisi, M., Merling, A., Krammer, P.H., Li-Weber, M., Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One, 2, 2007, e693.
17. [17] Hamacher-Brady, A., Stein, H.A., Turschner, S., Toegel, I., Mora, R., Jennewein, N., Efferth, T., Eils, R., Brady, N.R., Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J. Biol. Chem. 286 (2011), 6587–6601.
18. [18] Li, P.C., Lam, E., Roos, W.P., Zdzienicka, M.Z., Kaina, B., Efferth, T., Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 68 (2008), 4347–4351.
19. [19] Berdelle, N., Nikolova, T., Quiros, S., Efferth, T., Kaina, B., Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol. Cancer Ther. 10 (2011), 2224–2233.
20. [20] Wang, B., Hou, D., Liu, Q., Wu, T., Guo, H., Zhang, X., Zou, Y., Liu, Z., Liu, J., Wei, J., Gong, Y., Shao, C., Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol. Ther. 16 (2015), 1548–1556.
21. [21] Papanikolaou, X., Johnson, S., Garg, T., Tian, E., Tytarenko, R., Zhang, Q., Stein, C., Barlogie, B., Epstein, J., Heuck, C., Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget 5 (2014), 4118–4128.
22. [22] Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., Brady, N.R., Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2 (2015), 517–532.
23. [23] Luo, J., Zhu, W., Tang, Y., Cao, H., Zhou, Y., Ji, R., Zhou, X., Lu, Z., Yang, H., Zhang, S., Cao, J., Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat. Oncol., 9, 2014, 84.
24. [24] Beccafico, S., Morozzi, G., Marchetti, M.C., Riccardi, C., Sidoni, A., Donato, R., Sorci, G., Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis 36 (2015), 1071–1083.
25. [25] Greenshields, A.L., Shepherd, T.G., Hoskin, D.W., Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol. Carcinog., 2016.
26. [26] Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26 (2016), 165–176.
27. [27] Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23 (2016), 369–379.
28. [28] Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., Tang, D., Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63 (2016), 173–184.
29. [29] Roh, J.L., Kim, E.H., Jang, H.J., Park, J.Y., Shin, D., Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 381 (2016), 96–103.
30. [30] Nakamura, M., Nakatani, K., Uzawa, K., Ono, K., Uesugi, H., Ogawara, K., Shiiba, M., Bukawa, H., Yokoe, H., Wada, T., Fujita, S., Tanzawa, H., Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol. Rep. 14 (2005), 1281–1286.
31. [31] Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2010), 440–446.
32. [32] World Health Organization, second edition Gulideline for the Treatment of Malaria, 2010, World Health Organization, Geneva, Switzerland.
33. [33] The Nobel Prize in Physiology or Medicine, Nobel Foundation. 2015, The Nobel Assembly at Karolinska Institutet, Solna, Sweden, 2015.
34. [34] Tu, Y., The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17 (2011), 1217–1220.
35. [35] Winzeler, E.A., Manary, M.J., Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol., 15, 2014, 544.
36. [36] Hou, J., Wang, D., Zhang, R., Wang, H., Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 14 (2008), 5519–5530.
37. [37] Manz, D.H., Blanchette, N.L., Paul, B.T., Torti, F.M., Torti, S.V., Iron and cancer: recent insights. Ann. N. Y Acad. Sci. 1368 (2016), 149–161.
38. [38] Dixon, S.J., Stockwell, B.R., The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10 (2014), 9–17.
39. [39] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12 (2012), 564–571.
40. [40] Gorrini, C., Harris, I.S., Mak, T.W., Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12 (2013), 931–947.
41. [41] Wang, X.J., Sun, Z., Villeneuve, N.F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G.T., Wong, P.K., Zhang, D.D., Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29 (2008), 1235–1243.
42. [42] Kobayashi, A., Kang, M.I., Watai, Y., Tong, K.I., Shibata, T., Uchida, K., Yamamoto, M., Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell Biol. 26 (2006), 221–229.
43. [43] Ericsson, T., Blank, A., von Hagens, C., Ashton, M., Abelo, A., Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur. J. Clin. Pharm. 70 (2014), 1453–1463.
44. [44] Krishna, S., Ganapathi, S., Ster, I.C., Saeed, M.E., Cowan, M., Finlayson, C., Kovacsevics, H., Jansen, H., Kremsner, P.G., Efferth, T., Kumar, D., Randomised, A., Double Blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2 (2015), 82–90.
45. [45] Clark, R.L., Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod. Toxicol. 28 (2009), 285–296.
46. [46] Ho, W.E., Cheng, C., Peh, H.Y., Xu, F., Tannenbaum, S.R., Ong, C.N., Wong, W.S., Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma. Free Radic. Biol. Med. 53 (2012), 498–507.
47. [47] Cao, T.H., Jin, S.G., Fei, D.S., Kang, K., Jiang, L., Lian, Z.Y., Pan, S.H., Zhao, M.R., Zhao, M.Y., Artesunate protects against sepsis-induced lung injury via heme Oxygenase-1 modulation. Inflammation 39 (2016), 651–662.